Chiesi starts rare diseases division, ahead of potential Fabry disease filingItalian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch Share XChiesi starts rare diseases division, ahead of potential Fabry disease filinghttps://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/
Janssen trials ultrasound-guided approach to treating Crohn’sIn the highly competitive market for inflammatory diseases such as Crohn’s, pharma companies are looking for ways to Share XJanssen trials ultrasound-guided approach to treating Crohn’shttps://pharmaphorum.com/news/janssen-trials-ultrasound-guided-approach-to-treating-crohns/
UK leaders: Takeda’s Jon NealIn the first of a new series where we talk to GMs of UK pharma divisions, managing director Share XUK leaders: Takeda’s Jon Nealhttps://pharmaphorum.com/views-analysis-market-access/uk-leaders-takeda-jon-neal/
Takeda invests in patient-centric data firm SeqsterUS startup Seqster, which it claims to “put the person at the centre of healthcare”, has just attracted Share XTakeda invests in patient-centric data firm Seqsterhttps://pharmaphorum.com/news/takeda-invests-in-patient-centric-data-firm-seqster/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
Takeda sets sights on first-line lung cancer market with new Alunbrig dataPfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a Share XTakeda sets sights on first-line lung cancer market with new Alunbrig datahttps://pharmaphorum.com/news/takeda-sets-sights-on-first-line-lung-cancer-market-with-new-alunbrig-data/
Experts concerned over mixed results from Takeda’s dengue vaccineTakeda’s dengue vaccine has met its target of protection against the disease in children – but there are Share XExperts concerned over mixed results from Takeda’s dengue vaccinehttps://pharmaphorum.com/news/experts-concerned-over-mixed-results-from-takedas-dengue-vaccine/
Takeda nets $660m from product selloff to Germany’s StadaTakeda has divested another block of products it views as lying outside its main focus, selling various drugs Share XTakeda nets $660m from product selloff to Germany’s Stadahttps://pharmaphorum.com/news/takeda-nets-660m-from-product-selloff-to-germanys-stada/
Takeda buys coeliac drug licence from COUR PharmaceuticalsTakeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced Share XTakeda buys coeliac drug licence from COUR Pharmaceuticalshttps://pharmaphorum.com/news/takeda-buys-coeliac-drug-licence-from-cour-pharmaceuticals/
